Comparison of FAIM3 gene expression between new cases of ALL and relapsed ALL
Archives of Medical Laboratory Sciences,
Vol. 4 No. 3 (2018),
28 Dey 2019
https://doi.org/10.22037/amls.v4i3.25392
Abstract
Background: Acute lymphoblastic leukemia (ALL) is one of the major lymphoid malignancies and the most common hematologic malignancy in children. ALL is characterized by the presence of malignant lymphoblasts in the blood so that immature lymphocytes cannot become mature and thus do not have an adult cell function. Although it is not unusual in adults, it usually affects children. Most children with this disease are recovered from therapeutic protocols. But the relapse is common after recovery or during the treatment. Various factors are supposed to contribute to the relapse of the disease. One of these factors that is likely to be effective in the recurrence of ALL is the FAIM3 protein (an FCuR), or the Fas inhibitory molecule-3 (FAIM3). The aim of this study was to investigate FAIM3 (TOSO) as a new prognostic factor in ALL.
Materials and methods: In this study, 19 patients with newly diagnosed and 17 patients with relapsed ALL were included. FAIM3 gene expression was measured with the qRT-PCR method.
Results: The expression level of FAIM3 in relapsed patients was 5.44 folds higher than newly diagnosed ALL patients.
Conclusion: Prognosis of ALL is usually well-proven in children and can be cured. However, recurrence of the disease is common. At the molecular level, there are several factors that are referred to as the "factor involved in the relapse" of the disease. These factors increase the survival of the leukemic cells. According to the results of the present study, gene expression level of FAIM3 as an anti-apoptotic factor has increased in relapsed ALL lymphoblasts, compared with new diagnosed patients. Therefore, FAIM3 can be considered as a contributing factor in the relapse of the disease.
- ALL
- FAIM3
- relapse
- FCuR
- Toso
How to Cite
References
Pui C-H. Acute lymphoblastic leukemia: Springer; 2011.
Hoelzer D, Gökbuget N, Ottmann O, Pui C-H, Relling MV, Appelbaum FR, et al. Acute lymphoblastic leukemia. 2002; 2002(1):162-92.
Inaba H, Greaves M, Mullighan CGJTL. Acute lymphoblastic leukaemia. 2013; 381(9881):1943-55.
Clarke RT, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJJAodic. Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. 2016; 101(10):894-901.
Jonsson OG, Sartain P, Ducore JM, Buchanan GRJTJop. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes. 1990; 117(2):233-7.
Pui C-HJCoio. Acute lymphoblastic leukemia in children. 2000; 12(1):3-12.
Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. 2002; 1(2):133-43.
Nesbit Jr ME, Robison LL, Ortega JA, Sather HN, Donaldson M, Hammond DJC. Testicular relapse in childhood acute lymphoblastic leukemia: association with pretreatment patient characteristics and treatment. A report for Childrens Cancer Study Group. 1980; 45(8):2009-16.
Pui C-H, Evans WEJNEJoM. Treatment of acute lymphoblastic leukemia. 2006; 354(2):166-78.
Campana D. Detection of minimal residual disease in acute lymphoblastic leukemia. 2010.
Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. 1988; 71(1):123-31.
Tsukimoto I, Wong KY, Lampkin BCJNEJoM. Surface markers and prognostic factors in acute lymphoblastic leukemia. 1976; 294(5):245-8.
Nguyen K, Devidas M, Cheng S-C, La M, Raetz EA, Carroll WL, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. 2008; 22(12):2142.
Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. 2007; 109(3):944-50.
Nguyen X-H, Fattakhova G, Lang PA, Lang KS, Adam D, Föger N, et al. Response: antiapoptotic function of FAIM3 (Faim3) in death receptor signaling. 2012; 119(7):1790-1.
Pallasch CP, Wendtner CMJL, lymphoma. Overexpression of the Fas-inhibitory molecule FAIM3–a novel antiapoptotic factor in chronic lymphocytic leukemia. 2009; 50(3):498-501.
Lydyard P, Fanger MJI. Characteristics and function of Fc receptors on human lymphocytes. 1982; 47(1):1.
Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang D-W, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. 2009; 206(12):2779-93.
Ohno T, Kubagawa H, Sanders SK, Cooper MJJoEM. Biochemical nature of an Fc mu receptor on human B-lineage cells. 1990; 172(4):1165-75.
Shima H, Takatsu H, Fukuda S, Ohmae M, Hase K, Kubagawa H, et al. Identification of FAIM3/FAIM3 as an Fc receptor for IgM. 2009; 22(3):149-56.
Staal F, van der Burg M, Wessels L, Barendregt B, Baert M, Van den Burg C, et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. 2003; 17(7):1324.
Song Y, Jacob COJJoBC. The mouse cell surface protein FAIM3 regulates Fas/Fas ligand-induced apoptosis through its binding to Fas-associated death domain. 2005; 280(10):9618-26.
Vire B, David A, Wiestner AJTJoI. FAIM3, the Fcμ receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. 2011:1100532.
Honjo K, Kubagawa Y, Jones DM, Dizon B, Zhu Z, Ohno H, et al. Altered Ig levels and antibody responses in mice deficient for the Fc receptor for IgM (FcμR). 2012:201206567.
Lang P, Meryk A, Pandyra A, Brenner D, Brüstle A, Xu H, et al. FAIM3 regulates differentiation and activation of inflammatory dendritic cells during persistence-prone virus infection. 2015; 22(1):164.
Lang KS, Lang PA, Meryk A, Pandyra AA, Merches K, Lee K-H, et al. Reply to Honjo et al.: Functional relevant expression of FAIM3 on granulocytes. 2013; 110(28):E2542-E3.
Honjo K, Kubagawa Y, Kubagawa HJPotNAoS. Is FAIM3/IgM Fc receptor (FcμR) expressed by innate immune cells? 2013; 110(28):E2540-E1.
Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. 2005; 106(5):1831-8.
Richter G, Mollweide A, Hanewinkel K, Zobywalski C, Burdach SJSjoi. CD25 blockade protects T cells from activation‐induced cell death (AICD) via maintenance of FAIM3 expression. 2009; 70(3):206-15.
- Abstract Viewed: 117 times
- PDF Downloaded: 71 times